Predictive Biomarkers Market size was over USD 20.3 Billion in 2023 and is likely to exceed USD 29.5 Billion by the end of 2036, growing at over 18.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of predictive biomarkers is evaluated at USD 21 Billion. The reason behind the growth is the rising prevalence of chronic diseases, such as cancer, and diabetes across the globe. Predictive biomarkers help in predicting disease progression and assessing the risk of developing certain diseases. For instance, elevated levels of below 4.0 ng/mL prostate-specific antigen in the blood can be a predictive biomarker for prostate cancer and are the most used biomarker in the management of early prostate cancer. According to the data from the World Health Organization (WHO), over 422 million people around the world suffer from diabetes, and it causes about 1.6 million deaths every year, whereas cancer caused over 10 million deaths in 2020.
The growing geriatric population is believed to fuel the market growth since older populations are more prone to diseases such as cardiovascular disease, and also cancer. Hence, the demand for predictive biomarkers is expected to increase to diagnose age-related conditions. According to World Health Organization, the number of people 60 and older in the world is expected to double (2.1 billion) by 2050.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
18.9% |
|
Base Year Market Size (2023) |
USD 20.3 Billion |
|
Forecast Year Market Size (2036) |
USD 29.5 Billion |
|
Regional Scope |
|
Application (Screening, Analysis, Diagnosis, Prediction, Monitoring)
The prediction segment in the predictive biomarkers market is estimated to gain a robust revenue share in the coming years owing to rising demand for measuring the likelihood of results of any treatment procedure. Predictive biomarkers are frequently employed at all stages of the drug discovery and development process to show the connection between the biomarker and treatment outcome and determine whether a disease or condition is present. Owing to their ability to predict whether a patient will respond to a specific chemotherapy, predictive biomarkers aid in the optimization of treatment choices, and are highly used to forecast the effects of treatment on patients, which helps medical professionals to provide specific medications.
End-Use (Hospitals, Specialty Clinics, Research Institutes)
The research institutes segment in the predictive biomarkers market is set to garner a notable share shortly driven by the investment made by various key market players for the creation of novel biomarkers for diagnostic and therapeutic purposes, along with large-scale funds from the government and private organizations which have been given to groups working on the development of new drugs. Research centers contribute to advancements in technology that facilitate biomarker identification associated with specific diseases. Besides this, they conduct clinical trials to assess the utility of predictive biomarkers and promote awareness regarding the benefits of these biomarkers.
Our in-depth analysis of the global market includes the following segments:
|
Indication |
|
|
Application |
|
|
End-Use |
|
North American Market Forecast
Predictive biomarkers market in North America is predicted to account for the largest share of 35% by the end of 2036 backed by the advanced research and development activities in the healthcare sector. The U.S. healthcare industry benefits from an effective system of medical research and development and invests significantly in the creation of new diagnostic instruments, which is predicted to spur market expansion. These efforts can lead to the creation of new predictive biomarkers and also increase their availability & accessibility in the region.
APAC Market Statistics
The Asia Pacific Predictive Biomarkers market is estimated to be the second largest, during the forecast timeframe led by increasing spending in healthcare. For instance, health-related spending per person is higher in Australia, Japan, and Singapore, which has led to a rise in the awareness of early disease diagnosis among people living in those countries.
Predictive biomarkers are becoming more widely used in the area as a result, as they aid in disease prevention and early intervention. In Singapore, it is anticipated that by 2030, public and private spending on aged healthcare will increase to over USD 48 billion.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?